About MAIA Biotechnology, Inc. MAIA is a targeted ... progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product ...

PanGIA Biotech, a company advancing urine-based ... biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (PPBT ... today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

Issued on behalf of Oncolytics Biotech Inc. Specifically ... in activating anti-tumor immunity in PDAC,” (Abstract #2562) will be presented as a poster during the Developmental Therapeutics – ...

In a world shaped by biotechnology, why are so few college students exposed to its possibilities early on in their education?

PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc ...

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology ... studies and our research and development programs ...